ADMA Biologics Inc recently responded to a short-selling report, firmly stating that the report presents a serious distortion and confusion regarding the actual efficacy and competitive position of its product Asceniv in the intravenous immunoglobulin (IVIG) market.

ADMA Biologics Inc recently responded to a short-selling report, firmly stating that the report presents a serious distortion and confusion regarding the actual efficacy and competitive position of its product Asceniv in the intravenous immunoglobulin (IVIG) market.

老虎证券2026/03/27 11:24

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

The company emphasized that the allegations in the report fail to accurately reflect the clinical value and market positioning of Asceniv.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

ADMA Biologics Inc recently responded to a short-selling report, firmly stating that the report presents a serious distortion and confusion regarding the actual efficacy and competitive position of its product Asceniv in the intravenous immunoglobulin (IVIG) market.

You may also like

Crypto prices